The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10481 malaria professionals are enjoying the free benefits of MalariaWorld today

immunogenicity

Maintaining immunogenicity of blood stage and sexual stage subunit malaria vaccines when formulated in combination

May 4, 2020 - 14:04 -- Open Access
Author(s): 
Parzych EM, Miura K, Long CA, Burns JM Jr
Reference: 
PLoS ONE 15(4): e0232355

Eradication of Plasmodium falciparum malaria will likely require a multivalent vaccine, but the development of a highly efficacious subunit-based formulation has been challenging. We previously showed that production and immunogenicity of two leading vaccine targets, PfMSP119 (blood-stage) and Pfs25 (sexual stage), could be enhanced upon genetic fusion to merozoite surface protein 8 (PfMSP8). Here, we sought to optimize a Pfs25-based formulation for use in combination with rPfMSP1/8 with the goal of maintaining the immunogenicity of each subunit.

NOT Open Access | Immunogenicity and safety of the RTS,S/AS01 malaria vaccine co-administered with measles, rubella and yellow fever vaccines in Ghanaian children: A phase IIIb, multi-center, non-inferiority, randomized, open, controlled trial

March 23, 2020 - 14:50 -- NOT Open Access
Author(s): 
Asante KP, Ansong D, Ofori-Anyinam O, et al.
Reference: 
Vaccine. 2020 Mar 16. pii: S0264-410X(20)30358-3

To optimize vaccine implementation visits for young children, it could be efficient to administer the first RTS,S/AS01 malaria vaccine dose during the Expanded Programme on Immunization (EPI) visit at 6 months of age together with Vitamin A supplementation and the third RTS,S/AS01 dose on the same day as yellow fever (YF), measles and rubella vaccines at 9 months of age. We evaluated the safety and immunogenicity of RTS,S/AS01 when co-administered with YF and combined measles-rubella (MR) vaccines.

Long-term immunogenicity and immune memory response to the hepatitis B antigen in the RTS,S/AS01E malaria vaccine in African children: a randomized trial

January 24, 2020 - 15:04 -- Open Access
Author(s): 
Valéa I, Adjei S, Agbenyega T, et al.
Reference: 
Hum Vaccin Immunother. 2020 Jan 17:1-7

RTS,S/AS01E malaria vaccine contains the hepatitis B virus surface antigen and may thus serve as a potential hepatitis B vaccine. To evaluate the impact of RTS,S/AS01E when implemented in the Expanded Program of Immunization, infants 8–12 weeks old were randomized to receive either RTS,S/AS01E or a licensed hepatitis B control vaccine (HepB), both co-administered with various combinations of the following childhood vaccines: diphtheria-tetanus-acellular pertussis-Haemophilus influenzae type b, trivalent oral poliovirus, pneumococcal non-typeable Haemophilus influenzae protein D conjugate and human rotavirus vaccine.

NOT Open Access | Improving the immunogenicity and protective efficacy of a whole‐killed malaria blood‐stage vaccine by chloroquine

January 14, 2020 - 10:00 -- NOT Open Access
Author(s): 
Yong Fu, Xiao Lu, Feng Zhu, Yunxiang Zhao, Yan Ding, Lilin Ye, Bo Guo, Taiping Liu, Wenyue Xu
Reference: 
Parasite Immunology, Volume42, Issue1, January 2020, e12682

A whole‐killed malaria blood‐stage vaccine (WKV) is promising in reducing the morbidity and mortality of malaria patients, but its efficacy needs to be improved. We found that the antimalarial drug chloroquine could augment the protective efficacy of the WKV of Plasmodium yoelii. The direct antimalarial effect of chloroquine on parasites during immunization could be excluded, as the administration of chloroquine or chloroquine plus alum every two weeks had a slight effect on parasitemia, and an immunization with NP‐KLH (4‐hydroxy‐3‐nitrophenylacetyl Keyhole Limpet Hemocyanin) plus chloroquine could significantly promote the generation of NP‐specific antibodies. Additionally, alum was required for chloroquine to augment the immunogenicity of the pRBC lysate.

Comparison of immunogenicity and safety outcomes of a malaria vaccine FMP013/ALFQ in rhesus macaques (Macaca mulatta) of Indian and Chinese origin

December 3, 2019 - 15:22 -- Open Access
Author(s): 
Monica L. Martin, Alexis A. Bitzer, Andrew Schrader, Elke S. Bergmann-Leitner, Kim Soto, Xiaoyan Zou, Zoltan Beck, Gary R. Matyas and Sheetij Dutta
Reference: 
Malaria Journal 2019 18:377, 27 November 2019

Indian-origin rhesus (InR) are preferred for research, but strict export restrictions continue to limit their use. Chinese-origin rhesus (ChR), although easier to procure, are genetically distinct from InR and differ in their immune response to infectious agents, such as the Simian Immunodeficiency Virus. The most advanced malaria vaccine, RTS,S (GlaxoSmithKline), is based on the circumsporozoite protein (CSP) of Plasmodium falciparum.

Subscribe to RSS - immunogenicity